1. HBW Insight

Perrigo’s Formula To Drive Earnings Rebound Swings On Further Formula Business Recovery

 
• By Malcolm Spicer

“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.

(Source: Shutterstock)

A product line not among Perrigo Company PLC’s sales growth drivers in nearly 30 years making it is the fulcrum for the firm’s outlook, not the first US OTC oral contraceptive it launched eight months ago.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from HBW Insight

Astaxanthin Specialist AstaReal Diversifies With Garlic Supplement For Heart Health

 
• By Tom Gallen

Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.

Little Industry Opposition To FDA Plan To Remove Synthetic Dyes, Or Agreement They’re Unsafe

 
• By Malcolm Spicer

Dyes and colors which FDA says industries agree should no longer be used aren’t unsafe and are currently used only with the agency’s approval, industry stakeholders say. Center for Science in the Public Interest says the dyes are used “in tens of thousands of foods and beverages that are commonly consumed here in the United States.”

NAD Refers Men’s Hair Color Brand To FTC For Non-Compliance With Fast-Track SWIFT Decision

 
• By Eileen Francis

Plano, Texas-based Simpler Hair Color Inc. may face FTC enforcement action after it failed to comply with the National Advertising Division’s recommendations it discontinue the claim, “Rated #1 Men’s Hair Color,” associated with a consumer review website.

FDA Leadership Shuffle Continues: Lowell Zeta Returns As OPDP, OGD Leaders Depart

 
• By Sue Sutter and Derrick Gingery

Lowell Zeta, a senior counselor at the FDA from 2020 to 2021, returns as deputy commissioner for strategic initiatives. The agency also names a new acting CIO and acting CVM director, but OGD's Ted Sherwood and OPDP's Catherine Gray retired.

More from Recalls

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

 
• By Malcolm Spicer

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Check Contract Manufacturers' GMP Compliance, US FDA Warns Eye Drop Firm, Lip Balm Provider

 
• By Malcolm Spicer

Request to recall eye drops should be fulfilled promptly and businesses providing lip balms as promotional products must verify contract manufacturers are compliant, recent FDA warnings states. Additional letters went to Jordanian firm about testing alcohol for methane and to a Chinese firm advised that compliance with China’s quality control standards isn’t sufficient.

Valisure Puts FDA Under Microscope In Complaint On Ranitidine Tests Seeking Damages From GSK

 
• By Malcolm Spicer

Amended complaint filed 21 May after US Attorney General in March said the federal and state governments, named as co-plaintiffs, wouldn’t intervene and the court ordered the complaint unsealed. Complaint, initially filed in 2019, is critical of FDA, generally alleging agency failed to conduct sufficient oversight and evaluation of GSK’s testing data for ranitidine.